Ryu Kariyawasam-Chavez, Content Associate

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

LTOT opioid therapy declines, but gabapentinoid coprescribing rises—impact on chronic pain management, safety, and prescriptions.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Meitheal Pharmaceuticals launches propofol sedation vials for ICU and surgery, cutting waste and dosing errors with 3 single-dose sizes.